

Amendments to the Claims

This Listing of Claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. –2. (Cancelled)

3. (Currently Amended) A vaccine composition according to claim 1 wherein the comprising a proteosome adjuvant and at least one group A Streptococcal antigen attached to a hydrophobic moiety, wherein the antigen comprises a fragment an antigenic peptide between 6 and 25 amino acids in length of the M protein from the conserved C-terminal region of an *S. pyogenes* M protein of between 6 and 25 amino acids in length.

4. (Currently Amended) A—The vaccine composition according to claim 1—claim 3 wherein the antigen—antigenic peptide has the sequence ASREAKKQVEKALE ASREAKKQVEQKALE (SEQ ID NO:1).

5. (Currently Amended) A—The vaccine composition according to claim 2—3 wherein the antigen—antigenic peptide is flanked by amino acid sequences to maintain helical folding of the antigen.

6. (Currently Amended) A—The vaccine composition according to claim 5 wherein the peptide—antigen—antigenic peptide has the sequence KQAEDKVKASREAKKQVEKALEQLEDKVK (SEQ ID NO:2).

7. (Currently Amended) A vaccine composition according to claim 1 wherein comprising a proteosome adjuvant and a group A streptococcal antigen, wherein the antigen is selected from an MtsA peptide or a protein H peptide.

8. (Currently Amended) A-The vaccine composition according to claim 1-3 wherein the antigenic peptide further comprises a C- or N-terminal hydrophobic moiety is attached at the N-terminal end or C-terminal end of the antigen for insertion of the antigenic peptide into proteosome adjuvant vesicles complexing the antigen with the proteosome adjuvant.

9. (Currently Amended) A-The vaccine composition according to either claim 1-3 or claim 7 for parenteral or oral administration wherein the composition is formulated for mucosal administration.

10. (Currently Amended) A-The vaccine composition according to claim 9 for wherein mucosal administration is intranasal administration.

11. - 12. (Cancelled)

13. (Currently Amended) A-The vaccine composition according to claim 11-3 wherein administration of the composition to the an individual induces a mucosal immune response.

14. (Currently Amended) A-The vaccine composition according to claim 11-3, wherein administration of the vaccine composition induces a serum immune response.

15. (Currently Amended) A-The vaccine composition according to claim 11-9 wherein the vaccine composition is capable of treating or preventing a administered intranasally to the individual and treatment or prophylaxis of group A Streptococcal infection via is produced via reduction or prevention of reducing or preventing streptococcal group A bacterial colonisation of the throat.

16. (Currently Amended) A method of treatment ~~of~~or prophylaxis of group A Streptococcal infection in an individual comprising administering ~~a~~the vaccine composition according to either claim ~~1~~3 or claim 7 to the individual.

17. (Currently Amended) ~~A~~The method according to claim 16 wherein said vaccine composition is administered intranasally to said individual.

18. (Currently Amended) ~~A~~The method according to claim 17 wherein the treatment or prophylaxis of the group A Streptococcal infection is produced via prevention or reduction of bacterial colonisation of the throat.

19. (New) The vaccine composition according to claim 3 wherein the antigen further comprises a spacer peptide comprising at least two glycine residues, and wherein the spacer peptide links the antigenic peptide and the hydrophobic moiety.